Previous 10 | Next 10 |
Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease Palatin and FDA Reach Agreement on Path to NDA Submission, including Trial Design, Endpoints, Interim Assessment, and Patient Population On Track to Initiate Phase 3 Stu...
Palatin Announces New Additions to Its Senior Leadership Team Michael B. Raizman, M.D. - Chief Medical Officer James E. Hattersley - Senior Vice President, Business Development J. Don Wang, Ph.D. - Vice President, Product Development PR Newswire CRANBURY, N...
Palatin Announces Adjournment of Annual Meeting of Stockholders - Limited to Proposal 3, Amendment to Certificate of Incorporation to Increase Authorized Common Stock - Proposals 1, 2, and 4 were approved at the Annual Meeting - Scheduled to Reconvene July 8, 2021, 9:00 ...
Palatin Technologies, Inc. (PTN) Q3 2021 Earnings Conference Call May 17, 2021 11:00 AM Company Participants Carl Spana – President and Chief Executive Officer Steve Wills – Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participant...
Palatin Tech (PTN): FQ3 GAAP EPS of -$0.02 beats by $0.02.Revenue of $0.09M misses by $0.8M.Cash and cash equivalents of $68.6M.Shares +4.47% PM.Press Release For further details see: Palatin Tech EPS beats by $0.02, misses on revenue
Palatin Reports Financial Results for the Third Fiscal Quarter of 2021 and Provides Corporate Update -- Phase 3 Clinical Study of PL9643 in Patients with Dry Eye Disease Planned for Second Half Calendar 2021 -- Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Col...
Palatin Hosting Key Opinion Leader Webinar in Role of Melanocortin Agonists in Inflammation and the Treatment of Ocular Indications Primary focus on PL9643 - Phase 3 Clinical Study in Patients with Dry Eye Disease Planned for Second Half Calendar 2021 Webinar on Friday, May ...
Palatin to Report Third Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on May 17, 2021 PR Newswire CRANBURY, N.J. , May 13, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal...
Palatin Announces U.S. Patent Term Extension for Vyleesi® (bremelanotide injection) PR Newswire CRANBURY, N.J. , May 4, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines...
Biotech Penny Stocks On Robinhood To Watch Right Now Penny stocks are in a bright spotlight heading into the month ahead. With Monday marking the first trading day of May, it’s important to take time, analyze trends and get ready for what the market has in store. But, whether you...
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 PR Newswire CRANBURY, N.J. , May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 20...
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity PR Newswire Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar ye...
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 PR Newswire CRANBURY, N.J. , April 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (N...